aspirin and liraglutide

aspirin has been researched along with liraglutide in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N	1
Amin, T; Boyce, JA; Cahill, KN; Feng, C; Foer, D; Hayashi, H; Lai, J; Laidlaw, TM; Lin, A; Liu, T; McGill, A; Nagai, J; Newcomb, DC; Niswender, KD; Snyder, WE; Tani, Y	1

Other Studies

2 other study(ies) available for aspirin and liraglutide

Article	Year
Reducing CV risk in diabetes: An ADA update. The Journal of family practice, 2017, Volume: 66, Issue:5 Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones	2017
Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease. Journal of immunology (Baltimore, Md. : 1950), 2023, Dec-15, Volume: 211, Issue:12 Topics: Animals; Aspirin; Asthma; Asthma, Aspirin-Induced; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Inflammation; Interleukin-33; Liraglutide; Mice; Platelet Activation; Prospective Studies; Receptors, Thromboxane	2023

Article

Year

Reducing CV risk in diabetes: An ADA update.

The Journal of family practice, 2017, Volume: 66, Issue:5

Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones

2017

Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.

Journal of immunology (Baltimore, Md. : 1950), 2023, Dec-15, Volume: 211, Issue:12

Topics: Animals; Aspirin; Asthma; Asthma, Aspirin-Induced; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Inflammation; Interleukin-33; Liraglutide; Mice; Platelet Activation; Prospective Studies; Receptors, Thromboxane

2023